{
    "clinical_study": {
        "@rank": "48406", 
        "arm_group": {
            "arm_group_label": "Abiraterone acetate", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to provide access to abiraterone acetate for patients who have\n      completed 12 cycles of abiraterone acetate treatment in Clinical Study COU-AA-001 and\n      continue to receive clinical benefit from this treatment."
        }, 
        "brief_title": "An Expanded Access Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer Who Have Completed Clinical Study COU-AA-001", 
        "completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "condition": "Prostate Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Prostatic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is an open-label (identity of study drug will be known) extended access study to\n      evaluate the safety and efficacy of continued administration of abiraterone acetate in\n      patients who have completed 12 cycles of abiraterone acetate treatment in Clinical Study\n      COU-AA-001 and continue to receive clinical benefit from this treatment. Patients will\n      continue with the same dose regimen administered at the end of Study COU-AA-001 and will\n      receive a low-dose glucocorticoid daily. Patients will be followed every 3 months for\n      disease progression and survival for up to 3 years following study entry. Safety will be\n      monitored throughout the study up to 30 days after the last dose of study medication."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Completed 12 cycles of abiraterone acetate under study COU-AA-001\n\n          -  Last dose of abiraterone acetate within 14 days prior to treatment in this study\n\n          -  Demonstrates potential to gain clinical benefit with continued abiraterone acetate\n             treatment\n\n          -  Serum potassium level >=3.5 mmol/L\n\n          -  Eastern Cooperative Oncology Group Performance Status of <3 (Karnofsky Performance\n             Status >=30%)\n\n          -  Agrees to protocol-defined use of effective contraception\n\n        Exclusion Criteria:\n\n          -  Serious or uncontrolled co-existent non-malignant disease, including active and\n             uncontrolled infection\n\n          -  Uncontrolled hypertension\n\n          -  Abnormal liver function\n\n          -  Clinically significant heart disease as evidenced by a myocardial infarction in the\n             past 12 months, severe or unstable angina, or New York Heart Association (NYHA) Class\n             III or IV heart disease (patients with a history of atherosclerotic vascular disease\n             requiring coronary or peripheral artery bypass surgery may be enrolled provided the\n             surgery occurred at least 2 years prior to enrollment and after consultation with a\n             cardiologist to insure that the disease is stable)\n\n          -  Condition or situation which, in the investigator's opinion, may put the patient at\n             significant risk, may confound the study results, or may interfere significantly with\n             patient's participation in the study"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "54", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01664728", 
            "org_study_id": "CR016912", 
            "secondary_id": [
                "COU-AA-001EXT", 
                "2006-006755-12"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Abiraterone acetate", 
                "description": "Phase 2 maximum tolerated dose from Study COU-AA-001 taken orally once daily", 
                "intervention_name": "Abiraterone acetate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Abiraterone acetate", 
                "description": "prednisolone/prednisone 5 mg taken orally twice daily or dexamethasone 0.5 mg taken orally once daily", 
                "intervention_name": "Glucocorticoid", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Glucocorticoids"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Prostate neoplasms", 
            "Hormone refractory prostate cancer", 
            "Castration resistant prostate cancer", 
            "Castration refractory prostate cancer", 
            "Abiraterone acetate", 
            "CB7630"
        ], 
        "lastchanged_date": "April 18, 2013", 
        "link": {
            "description": "An Expanded Access Open Label Study of CB7630 (Abiraterone Acetate) in Patients with Advanced Prostate Cancer Who Have Completed CB7630 Clinical Study COU-AA-001", 
            "url": "http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&studyid=2388&filename=CR016912_CSR.pdf"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Sutton", 
                    "country": "United Kingdom"
                }
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Expanded Access Open Label Study of CB7630 (Abiraterone Acetate) in Patients With Advanced Prostate Cancer Who Have Completed CB7630 Clinical Study COU-AA-001", 
        "overall_official": {
            "affiliation": "Janssen Research & Development, LLC", 
            "last_name": "Janssen Research & Development, LLC Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of participants with serum prostate specific antigen (PSA) decline according to PSA Working Group criteria", 
                "safety_issue": "No", 
                "time_frame": "Screening, Cycle 1 Day 1 Pre-dose, every 3 months up to 3 years after study entry"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "every 3 months up to 3 years after study entry"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01664728"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of participants with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 30 days after the last dose of study medication"
            }, 
            {
                "measure": "Time to disease progression", 
                "safety_issue": "No", 
                "time_frame": "every 3 months up to 3 years after study entry"
            }, 
            {
                "measure": "Time to prostate specific antigen progression", 
                "safety_issue": "No", 
                "time_frame": "every 3 months up to 3 years after study entry"
            }, 
            {
                "measure": "Objective tumor response by Response Evaluation Criteria in Solid Tumors (RECIST)", 
                "safety_issue": "No", 
                "time_frame": "every 3 months up to 3 years after study entry"
            }
        ], 
        "source": "Janssen Research & Development, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Janssen Research & Development, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2007", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}